-
- Reimbursement Consulting, Healthcare Business Solutions
- Healthcare Market Research
- Healthcare Education, Healthcare Education And Training
- Hotline Assessments and Patient Assistance Programs
- Expanded Access Program
- Case Studies
- Market Research - Leveraging insight from Payors
- Comparative Cost Analysis - Pharmaceuticals
- Healthcare Reform Analysis
- Health Technology Assessment - Oncology
- Reimbursement Call Center and Patient Assistance Program Design - Multiple Product Classes
- Comparative Effectiveness Review - Diabetes
- Reimbursement Training and Field Reimbursement Call Tracking Tool
- Competitive Intelligence - Urology
- Product Commercialization and Reimbursement Landscape Analysis - Oncology
- Clinical Services Evaluation - Specialty Pharmacy
- Commercialization Strategy - Deep Vein Thrombosis
- Coverage Analysis - Drug Delivery System
- Reimbursement Coverage and Coding Analysis - Vascular Stents
- Health Economic Analysis - Rheumatoid Arthritis
- Health Economics Analysis - Diabetes Mellitus Blood Glucose Monitoring
- Expanded Access
- Comprehensive Clinical Analysis and Clinical Protocol Design - Migrane
- Outcomes Research Plan - Gastroenterology
- Clinical Compendium and Gap Analysis - Pain Management
- Reimbursement Landscape Analysis - Rare Bleeding Disorders (Hemophilia)
- Disease Area Review and Burden of Illness Analysis - Oncology
- Hospital Inpatient Payor Claims Analysis - Hospital Acquired Infections
- Health Economic Analysis - Orthopedics
- Market Valuation - Opioids
- Meta Analysis - HIV (Human Immunodeficiency Virus)
- AMCP Dossier - Dermatology
- Competitive Intelligence - Infectious Diseases
- Competitive Intelligence - Contraception
- Reimbursement Landscape Analysis - Urology
- Health Economics Analysis - Crohn's Disease
- Comprehensive Reimbursement and Health Economic Analysis - Neurovascular Disease
- Patient Assistance Program Design - Insulin Products
- Health Technology Assessment - Wound Therapy System
Case Studies
Health Economic Analysis - Rheumatoid Arthritis
Insight
Continuing its efforts to secure appropriate, ongoing reimbursement for its rheumatoid arthritis agent, a global health care company asked The Aequitas Group to review clinical evidence that would directly impact adoption and diffusion in spite of reimbursement changes. This clinical data supported a value analysis demonstrating the cost effectiveness of this agent.Strategy
The Aequitas Group developed a model to serve as an algorithm (decision analysis function) for testing assorted sequential therapy strategies, whereby the framework would serve as the backbone of a cost-effectiveness analysis. The analysis was developed from the provider perspective; the cost-effectiveness was developed from a payor perspective.Execution
By developing a decision analytic framework to delineate sequential therapy treatment options for the client’s product and in-class agents The Aequitas Group was able to form a direct comparison of relative strengths and weaknesses of such positioning for each agent as well as develop a model that yielded the cost and cost-effectiveness of such use. This model informed the client’s reimbursement strategy.© 2009 The Aequitas Group, Inc. All Rights Reserved.